Conference call: AbbVie Sees Q4 Adj EPS $3.83-$3.87 vs $3.89 Est; Sees Sales $18.400B vs $18.300B Est
Benzinga Newsdesk 2 days ago
NewsGuidanceHot
AbbVie (NYSE:ABBV) is looking for Q4 Adj EPS of $3.83-$3.87 vs $3.89 analyst estimate. sees sales of $18.400 billion vs $18.300 billion analyst estimate.
AbbVie (NYSE:ABBV) is looking for Q4 Adj EPS of $3.83-$3.87 vs $3.89 analyst estimate. sees sales of $18.400 billion vs $18.300 billion analyst estimate.